Free tool
FAERS Monitor: Brevibloc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019386 or its brand name (Brevibloc, Esmolol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
267
Serious
251
94% of reports
Hospitalization
94
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective36
- cardiac arrest21
- hypotension20
- bradycardia17
- product use issue15
- product use in unapproved indication12
- renal failure10
- ventricular fibrillation10
- hypertension9
- acute kidney injury8
- atrial fibrillation8
- death8
- hepatotoxicity8
- hyperbilirubinaemia8
- pulmonary oedema8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 4 |
| 2009 | 10 |
| 2010 | 6 |
| 2011 | 14 |
| 2012 | 6 |
| 2013 | 9 |
| 2014 | 7 |
| 2015 | 21 |
| 2016 | 17 |
| 2017 | 10 |
| 2018 | 15 |
| 2019 | 14 |
| 2020 | 13 |
| 2021 | 16 |
| 2022 | 14 |
| 2023 | 21 |
| 2024 | 11 |
| 2025 | 26 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,892 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ventricular fibrillationSignal | 10 | 71.0 | 38.6 | 621 |
| hyperbilirubinaemiaSignal | 8 | 60.9 | 30.8 | 413 |
| hepatotoxicitySignal | 8 | 28.3 | 14.3 | 184 |
| bradycardiaSignal | 17 | 25.3 | 15.9 | 373 |
| cardiac arrestSignal | 21 | 20.0 | 13.3 | 362 |
| pulmonary oedemaSignal | 8 | 14.1 | 7.1 | 85 |
| hypotensionSignal | 20 | 7.9 | 5.2 | 114 |
| atrial fibrillationSignal | 8 | 6.5 | 3.3 | 32 |
| product use issueSignal | 15 | 6.3 | 3.8 | 62 |
| renal failureSignal | 10 | 5.9 | 3.2 | 36 |
| acute kidney injurySignal | 8 | 4.1 | 2.1 | 16 |
| product use in unapproved indicationSignal | 12 | 3.8 | 2.2 | 22 |
| hypertensionSignal | 9 | 3.3 | 1.8 | 13 |
| drug ineffectiveSignal | 36 | 2.2 | 1.6 | 22 |
| death | 8 | 0.7 | 0.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.